Cytoreductive surgery and intraoperative hyperthermic chemoperfusion for advanced ovarian carcinoma
Journal of Surgical Oncology2005Vol. 90(2), pp. 51–56
Citations Over TimeTop 10% of 2005 papers
Trevor Reichman, Bernadette Cracchiolo, Jahir Sama, Margarette Bryan, Jonathan S. Harrison, Lillian Pliner, Lawrence E. Harrison
Abstract
The use of IHCP coupled with optimal cytoreduction is a safe and effective treatment for advanced ovarian carcinoma. However, the proper selection of patients who will benefit most from the therapy is essential for the success of the treatment.
Related Papers
- → Very Long-Term Outcome of the PRISON-IV Trial: 5-Year Clinical Follow-Up of Ultra-Thin Struts in CTO-PCI(2022)6 cited
- → Contemporary Percutaneous Left Atrial Appendage Occlusion Devices Have Same Long-Term Clinical Outcomes: A Meta-Analysis(2022)
- → So…Distal Radial Access for All?(2022)
- → Reply to the Letter to the Editor: Response to “Postoperative Myocardial Injury and Outcomes in Liver and Kidney Transplant Patients”(2022)
- → Do Clinical Trials Change Practice?(2022)